








FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE 	ATTY. DOCKET NO. LOMACEN.015C4	APPLICATION NO. 10/680,927
	APPLICANT William J. Wechter	
	FILING DATE September 12, 2003	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1.	4,144,325	03/13/79	Voyt	424	59	
	2.	6,410,589	06/25/02	Wechter	514	548	


FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	3.	0 350 913	01/17/90	EPO				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	4.	Isselbacher, et al., Ed's, Harrison's Principles of Internal Medicine, 13 th ed., Vol. 2, McGraw-Hill, New York, 1994.


EXAMINER 	DATE CONSIDERED 5/10/04
*EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. LOMACEN.015C4	APPLICATION NO. 10/660,927
 <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p>		APPLICANT William J. Wechter	
		FILING DATE September 12, 2003	GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1.	4,321,270	03/23/82	Sundeen	424	267	
	2.	4,914,197	04/03/90	Yamamoto et al.	536	117	
	3.	5,139,796	08/18/92	Barkalow et al.	426	3	
	4.	5,200,214	04/06/93	Barkalow et al.	426	3	
	5.	5,270,060	12/14/93	Foster et al.	426	3	
	6.	5,739,156	04/14/98	Bissett	514	458	
	7.	6,048,891	04/11/00	Wechter	514	456	
	8.	6,242,479	06/05/01	Wechter	514	456	
	9.	6,426,362	07/30/02	Miller et al.	514	458	
	10.	2002/0040053	04/04/02	Kondo et al.	514	456	
	11.	2002/0132845	09/19/02	Miller et al.	514	458	
	12.	2002/0143049	10/03/02	Miller et al.	514	458	
	13.	2003/0013656	01/16/03	Wang et al.	514	17	
	14.	2003/0013657	01/16/03	Wang et al.	514	17	
	15.	2003/0013846	01/16/03	Wang et al.	530	330	
	16.	2003/0013847	01/16/03	Wang et al.	530	330	
	17.	2003/0022818	01/30/03	Wang et al.	514	6	


FOREIGN PATENT DOCUMENTS



EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	18.	0 326 987 A2	8/89	EPO				
	19.	0 413 668 A2	2/91	EPO				
	20.	WO 96/05191	2/96	PCT				
	21.	WO 96/19215	6/96	PCT				


EXAMINER


DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED; INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. LOMACEN.015C4	APPLICATION NO. 10/660,927
 <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)</p>		APPLICANT William J. Wechter	
		FILING DATE September 12, 2003	GROUP 1614

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	22. Beharka, et al., "Vitamin E Status and Immune Function," Methods in Enzymology, Vol. 282, pp. 247-263, 1997.
	23. Benaksas, et al., Life Sciences, 52:1045-54 (1993)
	24. Bottje et al., "Effect of Dietary dl-alpha-Tocopherol on tissue alpha- and Gamma- Tocopherol and Pulmonary Hypertension Syndrome (Ascities in Broilers," Poultry Science, 76:1506-12, Abstract Only (1997)
	25. Burnett, et al., "Mechanisms of Phytochemical Inhibition . . .," American Chemical Society Symposium Series, pp. 45-58, 1998.
	26. Campo, et al., <i>Free Radical Biology and Medicine</i> , "Reduction of Myocardial Infarct Size in rat by IRFI-048, a selective analogue of Vitamin E", Vol. 16, pp.427-435 (1994)
	27. Campo, et al., <i>Pharmacology</i> , "Protective Effects of IRF-016, a New Antioxidant Agent, in Myocardial Damage, following coronary artery occlusion and reperfusion in the rat", 48:157-166 (1994)
	28. Campo, et al., <i>Research Comm. in Chem. Pathology and Pharmacology</i> , "IRFI-016, a new radical scavenger, limits ischemic damage following coronary artery occlusion in rats", Vol. 76, No., pp.287-303, (1992)
	29. Christen et al., "γ-Tocopheral Traps Mutagenic Electrophiles such as NO _x and Complements alpha-Tocopheral: Physiological Implications," Proc. Natl. Acad. Sci., USA, 94(7):3217-22 (1997)
	30. Elson, Charles E., "Impact of Palm Oil on Experimental Carcinogenesis," Vitamine E in Health and Disease, Packer & Fuchs eds, Chapter 39, pp. 533-45 (1993)
	31. Frei & Ames, "Relative Importance of Vitamine E in Antiperoxidative Defenses in Human Blood Plasma and Low-Density Lipoprotein (LDL)," Vitamine E in Health and Disease, Packer & Fuchs eds, Chapter 10, pp. 131-39 (1993)
	32. Germano, Carl, http://www.solgar.com/nutrition_library/articles/tocotrienols.html , Posted 11/27/1997, 4 pgs., "Tocotrienols in Health & Disease: A Novel Antioxidant in the Treatment of Hypercholesterolemia and Cancer."
	33. Kantoci et al., "Endogenous Natriuretic Factors 6: The Stereochemistry of a Natriuretic γ-Tocopherol Metabolite LLU-α," Journal of Pharmacology and Experimental Therapeutics, 282(2):648-656 (1997)
	34. Life Extension Foundation, http://lef.org/prod_desc/item564.html , (1995-1999), 2 pgs., "Gamma E Tocopherol Formula."
	35. Life Extension Foundation, http://lef.org/cgi-local/shop.pl/page=feb98_newproduct.html , (1995-1999), 3 pgs., "Not all Vitamin E is Created Equal."
	36. McLaughlin & Weihrauch, "Vitamin E Content of Foods," Journal of the American Dietetic Association, 75:6547-665 (1979)
	37. Meydani, Mohsen, "Vitamin E," The Lancet, 345:170-175 (1995)
	38. Meydani, S. & R. Tengerdy, "Vitamin E and Immune Response," Vitamine E in Health and Disease, Packer & Fuchs eds, Chapter 40, pp. 549-561 (1993)

EXAMINER 	DATE CONSIDERED 5/10/04
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 608; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. LOMACEN.015C4	APPLICATION NO. 10/660,927
 <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)</p>		APPLICANT William J. Wechter	
		FILING DATE September 12, 2003	GROUP 1114

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
<i>WJ</i>	39. Murray, David E. et al., "Endogenous Natriuretic Factors 7: Biospecificity of a Natriuretic γ -Tocopherol Metabolite LLU- α^1 ," The Journal of Pharmacology and Experimental Therapeutics, Vol. 282, pp. 657-662 (1997)
	40. Nando.net & The Associated Press, http://www.nando.net/newsroom/ntn/health/033197/health12-4931.html , 1997, 2 pgs., "Too Much Vitamin E Can be Harmful."
	41. Odeleve, et al., "The Potential Role of Vitamin E in the Treatment of Immunologic Abnormalities During Acquired Immune Deficiency Syndrome," Database Medline, 1991.
	42. Packer et al., "Significance of Vitamin E for the Athlete," Vitamine E in Health and Disease, Packer & Fuchs eds, (1993) Chapter 34, pp. 465-71
	43. Richardson et al., "Adhesion of Human Platelets Inhibited by Vitamin E," Vitamine E in Health and Disease, Packer & Fuchs eds, 1993, Ch. 24, pp. 297-311.
	44. Shigenaga et al., "Inflammation and NO _x -induced Nitration: Assay for 3-nitrotyrosine by HPLC with Electrochemical Detection," Proc. Natl. Acad. Sci. USA, 94(7):3211-3216 (1997)
	45. Speek et al., "Vitamin E Composition of Some Speed Oils as Determined by High-Performance Liquid Chromatography with Fluorometric Detection," Journal of Food Science, 50:121-124 (1985)
	46. Stone, et al., "Tocopherols and the Etiology of Colon Cancer," Journal of the National Cancer Institute, Vol 89, pp. 1006-1014, 1997.
	47. The Merck Index, 11 th edition, published by Merck & Co., Inc. (NJ), 1989, citation 9418, pg. 1495.
	48. Wechter et al., "A New Endogenous Natriuretic Factor: LLU- α ," Proc. Natl. Acad. Sci. USA, 93:6002-6007 (1996)
	49. Weichet et al., "Studien in der Gruppe der Vitamine K und E vi. Über die Darstellung von 2, 5, 7, 8, - Tetramethyl-2-(β -Carboxy-Äthyl)-6-Hydroxychroman und Dessen Oxydationsprodukt," Collection Czechoslov. Chem. Commun., 24:1689-1694 (1959) No Translation
	50. Official Monographs, "Vitamin E," "Vitamin E Preparation," and "Vitamin E Capsules," USP 23, pp. 1631-1633 (no date provided)
	51. "Myraid Genetics Plans to Launch the First Genetic Test for High Blood Pressure," Genetic Engineering News, pg. 27 (1997)
<i>WJ</i>	52. Yarita, et al., "Supercritical Fluid Chromatographic Determination of Cholesterol and Cholesteryl Esters in Serum on ODS-Silica Gel Column," Journal of Chromatography A., Vol. 679, pp. 329-334, 1994.

S:\DOCS\ESFESF-7218.DOC
102103

EXAMINER <i>WJ</i>	DATE CONSIDERED <i>5/10/04</i>
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 608; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	